Collegium Pharmaceutical (NASDAQ:COLL) Cut to “Buy” at Wall Street Zen

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Several other equities analysts also recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Down 1.1%

Shares of NASDAQ COLL opened at $35.20 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a 12-month low of $29.19 and a 12-month high of $50.79. The firm’s 50-day moving average price is $34.65 and its 200-day moving average price is $37.94. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 17.25 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same quarter last year, the business posted $1.49 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. On average, equities research analysts anticipate that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock valued at $2,120,000 after purchasing an additional 4,625 shares during the period. Jane Street Group LLC grew its holdings in shares of Collegium Pharmaceutical by 218.7% in the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after purchasing an additional 90,255 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after purchasing an additional 2,592 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.